Drug profile · INN
carbidopa
CARBIDOPA AND LEVODOPA
carbidopa (CARBIDOPA AND LEVODOPA) is a dopa decarboxylase inhibitor. Route of administration: enteral. Current US regulatory status: approved.
Drug details — carbidopa
- US status
- approved
- Class
- —
- Route
- ENTERAL
- Patents
- 19
- Programs
- 44
- Data quality
- 0.84
Quick answer
carbidopa (CARBIDOPA AND LEVODOPA) is a dopa decarboxylase inhibitor. Route of administration: enteral. Current US regulatory status: approved.
Key facts
Mechanism of action
DOPA decarboxylase inhibitor
Primary target: Aromatic-L-amino-acid decarboxylase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2026039538
MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS
granted -
WO 2025230528
MÉTHODES DE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE
granted -
US 2025250277
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
granted -
US 12370163
Levodopa dosing regimen
granted -
WO 2025147499
LUTIKIZUMAB DESTINÉ À ÊTRE UTILISÉ DANS UN TRAITEMENT DE L'HIDRADÉNITE SUPPURÉE
granted -
EP 4563165
PSMA-STEAP1-IMMUNGLOBULIN (DVD-IG)-MOLEKÜLE MIT ZWEIFACH VARIABLER DOMÄNE UND ARZNEIMITTELKONJUGATE
granted -
US 12303482
Levodopa dosing regimen
granted -
US 12303481
Levodopa dosing regimen
granted -
US 12295931
Levodopa dosing regimen
granted -
US 12263148
Levodopa dosing regimen
granted -
US 12263149
Levodopa dosing regimen
granted -
US 2025059280
METHODS OF TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
granted -
US 2025057837
Methods for Treating HCV
granted -
US 2025049789
METHODS OF TREATING ALOPECIA ARAETA
granted -
US 2025034157
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
granted -
US 12201596
Levodopa dosing regimen
granted -
US 12194150
Levodopa dosing regimen
granted -
US 12109185
Levodopa dosing regimen
granted -
US 11986449
Levodopa dosing regimen
granted
Frequently asked questions
What is carbidopa?
carbidopa (CARBIDOPA AND LEVODOPA) is a dopa decarboxylase inhibitor. Route of administration: enteral. Current US regulatory status: approved.
What is the brand name for carbidopa?
CARBIDOPA AND LEVODOPA is a marketed brand name for carbidopa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of carbidopa?
carbidopa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.